Binary Events Abound in Biotech
Long Ideas - As most biotech enthusiasts will be well-aware of, biotech is rife with binary events this week, many of which fall on Tuesday April 30. While … Continue Reading
Read NowMost Popular
Raised Guidance and Resolved Manufacturing Issues Support Alexion Shares
Long Ideas - Since our last report on Alexion Pharmaceuticals (ALXN) on April 5, shares have remained flat as continued concerns about the company’s manufacturing facilities and Soliris’ … Continue Reading
Read NowThe PropThink Recap: Finding Value in Biotech
Long Ideas - Synergy’s equity financing, which wrapped up last Tuesday, put the company in a strong position for a partnership (or M&A) negotiation regarding plecanatide. The stock … Continue Reading
Read NowSynergy is On Sale: Why This Opportunity Shouldn’t Be Missed
Long Ideas - On April 9, Synergy Pharmaceuticals (SGYP) reached a new 52-week intra-day high of $7.44, driven by a Cantor Fitzgerald analyst report highlighting more detailed trial … Continue Reading
Read NowIllumina’s Solid Quarter Highlights Macroeconomic Resilience & Market Opportunity
Long Ideas - On April 22, after the close of trading, Illumina (ILMN) released its Q1 2013 earnings, delivering another solid quarter in the face of perceived uncertainty. … Continue Reading
Read NowAveo’s Inflection Point: Tivozanib Likely To Receive Positive Advisory Vote, FDA Approval
Long Ideas - On May 2, 2013, AVEO Oncology (AVEO) is set to face the FDA’s Oncologic Drugs Advisory Committee (ODAC) for a review of the company’s New … Continue Reading
Read NowThe Beginning of a Shift at Tekmira: From Focus on Delivery, to Therapy
Long Ideas - Tekmira’s (TKMR) story over the last few years has largely been focused on its siRNA delivery technology, lipid nanoparticles (LNPs), and the ability of the … Continue Reading
Read Now